Lantern Pharma CEO: AI Spinout, Strong Lung Cancer Data and New Trials Ahead
New to The Street TV · 15:56
Lantern Pharma CEO Punit Sharma frames the Open Medicine AI spin-off as a way to commercialize the company’s RADAR AI drug-development stack for outside users, while Lantern keeps advancing precision-oncology assets—e...